Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
This page provides access to the complete catalogue of MARA Ratings® — independent, committee-determined reimbursement risk ratings, built for high-stakes market access and due diligence decisions across therapeutic areas, indications, and launch stages.
Each listing is a standardized reimbursement risk rating: the same ten-domain method for every asset, assessed in the payer context of the US, EU4, UK, and Japan, and calibrated against historical Health Technology Assessment (HTA) decisions.
A MARA Rating is a standardized risk signal, not an advisory opinion. It is structured, evidence-linked, and comparable across assets — an independent benchmark for pricing, reimbursement, and market-access assumptions before major capital allocation, licensing, M&A, or launch commitments are made. Once published, a rating stays on the record.
These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and
These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and